Notably, fludarabine (Figure 3B) and oxaliplatin (Figure 3C) exhibited elevated drug scores in HCC tissues with the XIRP2 mutation, suggesting a potential resistance to these drugs in HCC tissues with the XIRP2 mutation. This evidence concerns the gene XIRP2 and hepatocellular carcinoma.